傲農生物(603363.SH):擬將12件商標轉讓給福建益昕葆、將3件商標授權許可給江西益昕葆使用
格隆匯3月17日丨傲農生物(603363.SH)公佈,公司擬將12件商標轉讓給福建益昕葆生物製藥有限公司(簡稱“福建益昕葆”),轉讓價格為人民幣49.86萬元;公司擬將3件商標授權許可給江西益昕葆生物製藥有限公司(簡稱“江西益昕葆”)使用,許可使用費為9000元/年,此次許可使用1年;公司全資子公司漳州傲農牧業科技有限公司(簡稱“漳州傲農”)擬將3件商標授權許可給福建益昕葆使用,許可使用費為9000元/年,此次許可使用1年;公司全資子公司漳州傲農擬將4件商標授權許可給江西益昕葆使用,許可使用費為12,000元/年,此次許可使用1年。此次轉讓所涉及的12件商標的評估值為49.86萬元,交易價格為49.86萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.